Research groups

The group is investigating cellular mechanisms, which drive the development and metastatic growth of ovarian cancer. By using patient-derived organoids from solid tumour deposits we hope to identify key events that lead to cellular transformation, define response to therapy, and clonal evolution during disease progression. In this context, the role of homology-directed repair (HDR) mechanisms is of particular interest, as well as its involvement in the maintenance of stemness and growth potential of this deadly malignancy.

As a member of consortium OVA PDM (“Personalising the clinical decision making in ovarian cancer through patient-derived in vitro models”) ( ERA PerMed, Funding BMBF), based on in vitro response of ovarian cancer PDOs we aim to identify new biomarkers of PARPi and characterize hallmarks of PARP sensitivity.